HUP0204475A2 - Enhancing the circulating half-life of antibody-based fusion proteins - Google Patents
Enhancing the circulating half-life of antibody-based fusion proteinsInfo
- Publication number
- HUP0204475A2 HUP0204475A2 HU0204475A HUP0204475A HUP0204475A2 HU P0204475 A2 HUP0204475 A2 HU P0204475A2 HU 0204475 A HU0204475 A HU 0204475A HU P0204475 A HUP0204475 A HU P0204475A HU P0204475 A2 HUP0204475 A2 HU P0204475A2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- life
- circulating half
- based fusion
- fusion proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18176800P | 2000-02-11 | 2000-02-11 | |
| PCT/US2001/004455 WO2001058957A2 (en) | 2000-02-11 | 2001-02-09 | Enhancing the circulating half-life of antibody-based fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0204475A2 true HUP0204475A2 (en) | 2003-04-28 |
Family
ID=22665708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0204475A HUP0204475A2 (en) | 2000-02-11 | 2001-02-09 | Enhancing the circulating half-life of antibody-based fusion proteins |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7091321B2 (de) |
| EP (1) | EP1252192B1 (de) |
| JP (2) | JP5179689B2 (de) |
| CN (1) | CN1406249B (de) |
| AT (1) | ATE336514T1 (de) |
| AU (1) | AU4314801A (de) |
| CA (1) | CA2399832C (de) |
| CY (1) | CY1105725T1 (de) |
| DE (1) | DE60122286T2 (de) |
| DK (1) | DK1252192T3 (de) |
| ES (1) | ES2269366T3 (de) |
| HU (1) | HUP0204475A2 (de) |
| MX (1) | MXPA02007733A (de) |
| NO (1) | NO20023774D0 (de) |
| PT (1) | PT1252192E (de) |
| WO (1) | WO2001058957A2 (de) |
Families Citing this family (302)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1037927E (pt) | 1997-12-08 | 2004-10-29 | Emd Lexigen Res Ct Corp | Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US7387772B1 (en) | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR20020018197A (ko) * | 1999-05-19 | 2002-03-07 | 추후보정 | Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| BR0013231A (pt) | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Complexos citocina-anticorpo múltiplos |
| EP1228214A2 (de) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietinformen mit verbesserten eigenschaften |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| JP5390055B2 (ja) | 2000-06-29 | 2014-01-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強 |
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| HUP0303428A2 (hu) | 2001-03-07 | 2004-01-28 | Merck Patent Gmbh. | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| KR100900166B1 (ko) | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | 재조합 종양 특이적 항체 및 이들의 용도 |
| ATE542137T1 (de) * | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| PT1471974E (pt) * | 2002-02-06 | 2007-10-12 | Ares Trading Sa | Factor de necrose tumural combinado com interferão em doenças desmielinizantes |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CN100432105C (zh) | 2002-12-17 | 2008-11-12 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| EP1673395A1 (de) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Veränderungen der serum-halbwertszeiten von fc-fusionsprotein durch mutagenese der position 250, 314 und/oder 428 der schweren kette der konstanten region von ig |
| PT1699822E (pt) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| AU2005203962C1 (en) | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| AU2005206277B2 (en) * | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
| AU2005277641A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| CN100429233C (zh) * | 2005-02-03 | 2008-10-29 | 上海长海医院 | 一种重组融合蛋白及其制备方法及用途 |
| HUE025945T2 (en) | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| US8008443B2 (en) * | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
| WO2007005612A2 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP1943332A4 (de) | 2005-10-14 | 2011-04-13 | Medimmune Inc | Zellpräsentation von antikörperbibliotheken |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP2511298B1 (de) * | 2005-10-31 | 2019-01-16 | Oncomed Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Behandlung von Krebs unter Verwendung von menschlichen FZD Rezeptoren |
| EP2270050B1 (de) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-C19 Antikörper mit reduzierter Immunogenizität |
| EP1966238B1 (de) * | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40-varianten mit verbesserter stabilität |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
| WO2007103469A2 (en) | 2006-03-06 | 2007-09-13 | Aeres Biomedical Ltd. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| ATE555383T1 (de) | 2006-06-22 | 2012-05-15 | Novo Nordisk As | Lösliche heterodimere rezeptoren und ihre verwendung |
| ES2352561T3 (es) | 2006-06-30 | 2011-02-21 | Conaris Research Institute Ag | Dímeros de sgp 130fc mejorados. |
| WO2008003473A2 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| EP1878747A1 (de) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-hergestellte Antikörper |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| CL2007002609A1 (es) * | 2006-09-08 | 2008-04-18 | Genentech Inc | Antagonista de wnt que comprende un componente del dominio frizzled y un dominio fc; secuencia de acidos nucleicos que lo codifica; composicion que lo comprende; y su uso para tratar trastornos de proliferacion celular. |
| CA2673459C (en) * | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
| EP2703011A3 (de) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen |
| CN105175553B (zh) * | 2007-05-30 | 2019-11-22 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| KR100897938B1 (ko) * | 2007-05-30 | 2009-05-18 | 주식회사 제넥신 | 면역글로불린 융합 단백질 |
| EP1997830A1 (de) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung |
| WO2009006520A1 (en) * | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DK2245064T3 (da) | 2007-12-21 | 2014-10-27 | Medimmune Ltd | BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa) |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| CA2715043C (en) * | 2008-02-05 | 2021-02-16 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
| CN102066575A (zh) * | 2008-04-18 | 2011-05-18 | 雅培制药有限公司 | 结合蛋白体内半衰期的体外估测 |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| US20110274650A1 (en) | 2009-01-21 | 2011-11-10 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| SG175233A1 (en) | 2009-04-22 | 2011-11-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| CA2766405A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | Engineered fc regions for site-specific conjugation |
| CA2772240C (en) | 2009-08-17 | 2017-12-05 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| CN102741275B (zh) | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| AU2010303415B2 (en) | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| CN102770458A (zh) * | 2009-12-02 | 2012-11-07 | 阿塞勒隆制药公司 | 用于增加Fc融合蛋白的血清半寿期的组合物和方法 |
| WO2011069164A2 (en) | 2009-12-06 | 2011-06-09 | Biogen Idec Ma Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| ES2678143T3 (es) | 2010-01-19 | 2018-08-09 | President And Fellows Of Harvard College | Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos |
| US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| WO2011123785A2 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP3508573A1 (de) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systeme für faktor viii-verarbeitung und verfahren davon |
| PT3552619T (pt) | 2010-07-09 | 2025-10-23 | Bioverativ Therapeutics Inc | Polipéptidos de fator ix e métodos de uso dos mesmos |
| EP2603526A1 (de) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| RU2566267C2 (ru) | 2010-09-14 | 2015-10-20 | Ф. Хоффманн-Ля Рош Аг | Способ очистки пегилированного эритропоэтина |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| EP2714738B1 (de) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalente und monovalente multispezifische komplexe und ihre verwendungen |
| EP2718328A4 (de) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum |
| EP2537933A1 (de) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine |
| EP3626739A1 (de) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Leichtkettige immunglobulinfusionsproteine und verfahren zur verwendung davon |
| US9382305B2 (en) | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2012282875B2 (en) | 2011-07-08 | 2016-04-21 | Bioverativ Therapeutics Inc. | Factor VIII chimeric and hybrid polypeptides, and methods of use thereof |
| WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
| WO2013016454A1 (en) | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
| PT2760471T (pt) | 2011-09-30 | 2017-03-22 | Dana Farber Cancer Inst Inc | Péptidos terapêuticos |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| EP3539982B1 (de) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür |
| SMT201800586T1 (it) | 2012-01-12 | 2019-01-11 | Bioverativ Therapeutics Inc | Riduzione dell'immunogenicita' contro il fattore viii negli individui che si sottopongono alla terapia con fattore viii |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| EP2822577B1 (de) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Rekombinante faktor-viii-proteine |
| CA2866126A1 (en) * | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| WO2013164694A1 (en) | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| CN104812775B (zh) | 2012-07-25 | 2019-05-03 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| ES2633894T3 (es) * | 2012-08-02 | 2017-09-25 | F. Hoffmann-La Roche Ag | Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| TWI810729B (zh) | 2012-09-25 | 2023-08-01 | 美商百歐維拉提夫治療公司 | Ｆｉｘ多肽的應用 |
| US10391152B2 (en) | 2012-10-18 | 2019-08-27 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| EP2911691B1 (de) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln |
| EP3446700A1 (de) | 2012-10-30 | 2019-02-27 | Bioverativ Therapeutics Inc. | Verfahren zur verwendung von fviii-polypeptid |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| EP2956468B1 (de) | 2013-02-12 | 2020-06-10 | Bristol-Myers Squibb Company | Tangentialstromfiltration auf der basis von proteinrückfaltungsverfahren |
| PL2970512T3 (pl) | 2013-03-12 | 2019-03-29 | Biocon Limited | Immunomodulujące białka fuzyjne i sposoby ich otrzymywania |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| ES2926798T3 (es) | 2013-03-15 | 2022-10-28 | Bioverativ Therapeutics Inc | Formulaciones de polipéptido de factor VIII |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| TWI828269B (zh) | 2013-03-15 | 2024-01-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
| NZ629816A (en) | 2013-03-15 | 2017-07-28 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| EP2968503B1 (de) | 2013-03-15 | 2018-08-15 | Intrinsic LifeSciences LLC | Anti-hepcidin-antikörper und verwendungen davon |
| KR102539359B1 (ko) | 2013-04-19 | 2023-06-02 | 싸이튠 파마 | 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료 |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US9988617B2 (en) | 2013-05-21 | 2018-06-05 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| PT3052192T (pt) | 2013-10-02 | 2020-09-24 | Medimmune Llc | Anticorpos neutralizantes anti-influenza a e suas utilizações |
| EP3082848B1 (de) | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Pharmakokinetische werkzeuge für populationen und verwendungen davon |
| CN106029694A (zh) | 2013-12-06 | 2016-10-12 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| EP3546474B1 (de) | 2013-12-18 | 2021-07-07 | President and Fellows of Harvard College | Crp-erfassung/-detektion von grampositiven bakterien |
| CA2934644C (en) | 2013-12-24 | 2023-11-21 | Argen-X N.V. | Fcrn antagonists and methods of use |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| EP3105246B1 (de) | 2014-02-10 | 2021-03-31 | Merck Patent GmbH | Gezielte tgf-beta-hemmung |
| EP2915569A1 (de) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN113491766A (zh) | 2014-03-14 | 2021-10-12 | 达纳－法伯癌症研究所公司 | 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法 |
| SG11201607642RA (en) | 2014-03-24 | 2016-10-28 | Biogen Ma Inc | Lyophilized factor ix formulations |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| AU2015271709B2 (en) | 2014-06-06 | 2020-11-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| CA2954780A1 (en) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| UA125637C2 (uk) | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| EP3226888B1 (de) | 2014-12-01 | 2021-04-21 | Ferring B.V. | Verabreichung eines selektiven il-6-transsignalisierenden inhibitors |
| RS65665B1 (sr) | 2014-12-01 | 2024-07-31 | Ferring Bv | Selektivne kompozicije inhibitora il-6-trans-signalizacije |
| MY187045A (en) | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| KR102720769B1 (ko) | 2015-03-09 | 2024-10-22 | 아르제넥스 비브이 | FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법 |
| MX2017012966A (es) | 2015-04-10 | 2018-06-06 | Amgen Inc | Muteinas de interleuquina 2 para la expansion de celulas t regulatorias. |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EA035412B1 (ru) | 2015-05-29 | 2020-06-10 | Бристол-Майерс Сквибб Компани | Антитела к ox40 и их применение |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| AU2016298227B9 (en) | 2015-07-30 | 2019-10-31 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| CN108289928B (zh) | 2015-08-06 | 2024-09-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
| CN108136010A (zh) | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| CA3005855A1 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| CA3016187A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| CN108884142A (zh) | 2016-03-16 | 2018-11-23 | 梅里麦克制药股份有限公司 | 用于癌症治疗的工程化trail |
| CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| US10968279B2 (en) | 2016-05-09 | 2021-04-06 | Bristol-Myers Squibb Company | TL1A antibodies and uses thereof |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| AU2017295037B2 (en) | 2016-07-15 | 2021-07-22 | F. Hoffmann-La Roche Ag | Method for purifying PEGylated erythropoietin |
| KR20190039200A (ko) | 2016-08-12 | 2019-04-10 | 메르크 파텐트 게엠베하 | 암에 대한 조합 요법 |
| US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| CN110662770A (zh) | 2016-11-23 | 2020-01-07 | 比奥维拉迪维治疗股份有限公司 | 结合凝血因子ix和凝血因子x的双特异性抗体 |
| JP2019536794A (ja) | 2016-12-02 | 2019-12-19 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固因子に対する免疫寛容を誘導する方法 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| SI3558391T1 (sl) | 2016-12-23 | 2022-06-30 | Immunogen, Inc. | Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe |
| AU2017382234B2 (en) | 2016-12-23 | 2025-01-30 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
| US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| EP3600429B1 (de) * | 2017-03-20 | 2023-10-25 | Bio-Techne Corporation | Il-37-fusionsprotein und verfahren zur herstellung und verwendung davon |
| CN111094335B (zh) | 2017-05-15 | 2022-08-23 | 罗切斯特大学 | 广泛中和的抗流感单克隆抗体及其用途 |
| US20200299400A1 (en) | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| EP3694552A1 (de) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap-antikörper und verwendungen davon |
| US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| PH12020550661A1 (en) | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| JP7358361B2 (ja) | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| WO2019154776A1 (en) | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| AU2019248547B2 (en) | 2018-04-02 | 2025-07-17 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| EP3802590A2 (de) | 2018-06-08 | 2021-04-14 | Argenx BVBA | Zusammensetzungen und verfahren zur behandlung von immunthrombozytopenie |
| MX2020013466A (es) | 2018-06-26 | 2021-04-19 | Immunogen Inc | Inmunoconjugados dirigidos a adam9 y métodos para usarlos. |
| TWI819024B (zh) | 2018-07-09 | 2023-10-21 | 美商戊瑞治療有限公司 | 結合至ｉｌｔ４的抗體 |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| SG11202103064YA (en) | 2018-10-29 | 2021-05-28 | Hoffmann La Roche | Antibody formulation |
| WO2020093024A2 (en) | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Methods of administering anti-tim-3 antibodies |
| JP2022505925A (ja) | 2018-11-01 | 2022-01-14 | メルク パテント ゲーエムベーハー | 抗ｔｉｍ－３抗体 |
| JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル－マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
| WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| JP7797198B2 (ja) | 2018-12-21 | 2026-01-13 | オーエスイー・イミュノセラピューティクス | ヒトｐｄ－１に対する二機能性分子 |
| BR112021012040A2 (pt) | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula anti-pd-1/sirpa bifuncional |
| AU2019406452B2 (en) | 2018-12-21 | 2021-09-16 | Ose Immunotherapeutics | Humanized anti-human-PD-1 antibody |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| EP3914622A1 (de) | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Antikörper gegen il-7r-alpha-untereinheit und deren verwendungen |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2020172631A2 (en) | 2019-02-21 | 2020-08-27 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| AU2020279112A1 (en) | 2019-05-17 | 2021-12-02 | Xencor, Inc. | IL-7-Fc-fusion proteins |
| EP3980063A1 (de) | 2019-06-07 | 2022-04-13 | Argenx BVBA | Pharmazeutische formulierungen von fcrn-inhibitoren zur subkutanen verabreichung |
| CN114144435B (zh) | 2019-07-15 | 2024-06-25 | 百时美施贵宝公司 | 针对人trem-1的抗体及其用途 |
| EP3999543A1 (de) | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Anti-trem-1-antikörper und verwendungen davon |
| UY38836A (es) | 2019-08-13 | 2021-02-26 | Amgen Inc | Muteínas de interleucina-2 para la expansión de células t reguladoras |
| MX2022003204A (es) | 2019-09-19 | 2022-04-18 | Bristol Myers Squibb Co | Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido. |
| WO2021067863A2 (en) | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| KR20220148804A (ko) | 2020-01-08 | 2022-11-07 | 아르젠엑스 비브이 | 천포창 장애의 치료 방법 |
| JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾ｉｌ－２ポリペプチドおよびその使用 |
| EP4090674A4 (de) | 2020-01-14 | 2024-01-24 | Synthekine, Inc. | Vorgespannte il2-muteins-verfahren und -zusammensetzungen |
| JP7745556B2 (ja) | 2020-02-21 | 2025-09-29 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７結合分子及びその使用 |
| CA3170570A1 (en) | 2020-04-01 | 2021-10-07 | James J. KOBIE | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
| KR20230002261A (ko) | 2020-04-28 | 2023-01-05 | 더 락커펠러 유니버시티 | 항-sars-cov-2 중화 항체 및 이의 사용 방법 |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| EP4175650A1 (de) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4240758A1 (de) | 2020-11-04 | 2023-09-13 | The Rockefeller University | Neutralisierende anti-sars-cov-2-antikörper |
| WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| EP4263606A1 (de) | 2020-12-17 | 2023-10-25 | Ose Immunotherapeutics | Bifunktionelle anti-pd1/il-7 moleküle |
| US20240059763A1 (en) | 2020-12-18 | 2024-02-22 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
| EP4277926A1 (de) | 2021-01-15 | 2023-11-22 | The Rockefeller University | Neutralisierende anti-sars-cov-2-antikörper |
| EP4314068A1 (de) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antikörper gegen gespaltenes cdcp1 und verwendungen davon |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| WO2023281485A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| KR20240040134A (ko) * | 2021-07-09 | 2024-03-27 | 브라이트 피크 테라퓨틱스 아게 | 항체 접합체 및 이의 제조 |
| EP4366780A1 (de) * | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Synthetische il-7 und il-7-immunocytokine |
| EP4408468A4 (de) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | Mehrere formate molekularer komplexe |
| EP4469159A1 (de) | 2022-01-27 | 2024-12-04 | The Rockefeller University | Breit neutralisierende anti-sars-cov-2-antikörper gegen die n-terminale domäne des spike-proteins und verfahren zur verwendung davon |
| CA3258004A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/HSA BONDING MOLECULES AND METHODS OF USE |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| AU2023312054A1 (en) | 2022-07-22 | 2025-01-23 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
| EP4565610A1 (de) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunktionelles molekül gegen cd28 |
| CN121219315A (zh) | 2023-03-03 | 2025-12-26 | 塞德斯医疗公司 | 抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体 |
| EP4688851A1 (de) | 2023-03-27 | 2026-02-11 | LAVA Therapeutics N.V. | Nectin-4-bindende wirkstoffe und verfahren zur verwendung |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| KR20260041867A (ko) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법 |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| WO2025072888A2 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19 |
| WO2025085489A1 (en) | 2023-10-17 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025133694A1 (en) | 2023-12-20 | 2025-06-26 | argenx BV | Fcrn/hsa-binding molecules and methods of use |
| WO2025155877A2 (en) | 2024-01-18 | 2025-07-24 | The Regents Of The University Of California | Antibodies binding to pad4 and uses thereof |
| WO2025174974A1 (en) | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US20260092096A1 (en) | 2024-05-14 | 2026-04-02 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| WO2025245176A1 (en) | 2024-05-22 | 2025-11-27 | Bristol-Myers Squibb Company | Multispecific antibody constructs |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| US20250376536A1 (en) | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Multispecific anti-cd40 / anti-fap antibodies and uses thereof |
| WO2025255405A1 (en) | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Anti-fap antibodies and uses thereof |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| WO2026068750A1 (en) | 2024-09-27 | 2026-04-02 | Biomunex Pharmaceuticals | Antibodies that specifically bind mucosal associated invariant t (mait) cells |
| US20260115307A1 (en) | 2024-10-31 | 2026-04-30 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
Family Cites Families (227)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
| EP0158198A1 (de) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA und ihre Verwendung |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
| US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
| US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
| EP0237019A3 (de) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens |
| JPS63267278A (ja) | 1986-03-14 | 1988-11-04 | Toray Ind Inc | インタ−フエロン結合体を暗号化する塩基配列 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DK173067B1 (da) * | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| EP0307434B2 (de) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Geänderte antikörper |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
| US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
| ATE88900T1 (de) | 1987-09-02 | 1993-05-15 | Ciba Geigy Ag | Konjugate von interferon alpha mit immunglobulinen. |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
| US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
| DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues |
| US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US6750329B1 (en) | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0479909B1 (de) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispezifische reagenzien für die aids-therapie |
| EP0406857B1 (de) | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteine und deren Herstellung |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| DE69030579T2 (de) | 1989-09-20 | 1997-11-13 | Abbott Lab | Verfahren zur herstellung von fusionsproteinen |
| AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| DK0790255T3 (da) | 1989-12-22 | 2007-11-26 | Hoffmann La Roche | Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| JPH07507440A (ja) | 1990-03-02 | 1995-08-24 | レプリゲン・コーポレーション | 結合親和性を高めた抗体構築物 |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| WO1992002240A2 (en) | 1990-07-27 | 1992-02-20 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| WO1992008801A1 (en) | 1990-11-09 | 1992-05-29 | Abbott Laboratories | Bridging antibody fusion constructs |
| CA2095852C (en) | 1990-12-05 | 2001-05-08 | Uffe Lovborg | Proteins with changed epitopes and methods for the production thereof |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
| ATE173763T1 (de) | 1991-08-30 | 1998-12-15 | Hutchinson Fred Cancer Res | Hybride cytokine |
| US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
| US5376367A (en) | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
| US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| DE69333433T2 (de) | 1992-04-01 | 2004-12-02 | The Rockefeller University | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
| AU687733B2 (en) | 1992-04-01 | 1998-03-05 | Rockefeller University, The | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| DE4228839A1 (de) * | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| EP1757695A3 (de) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostata-spezifisches Membranantigen |
| US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| KR960701988A (ko) | 1993-04-20 | 1996-03-28 | 윌리엄 에스. 로빈슨 | 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents) |
| WO1994024160A2 (en) | 1993-04-21 | 1994-10-27 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| WO1994025609A1 (en) | 1993-04-28 | 1994-11-10 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
| CN1125401A (zh) | 1993-04-29 | 1996-06-26 | 艾博特公司 | 促红细胞生成素类似物组合物和方法 |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
| WO1995021258A1 (en) | 1994-02-01 | 1995-08-10 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fusion proteins that include antibody and nonantibody portions |
| WO1995028427A1 (en) | 1994-04-15 | 1995-10-26 | Imclone Systems Incorporated | Chimeric interleukin-3/mutein interleukin-6 lymphokine |
| ATE355379T1 (de) | 1994-04-26 | 2006-03-15 | Childrens Medical Center | Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| CA2190101A1 (en) | 1994-05-13 | 1995-11-23 | Donald Leonard Nicholas Cardy | Improvements in or relating to peptide delivery |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| HUT76369A (en) | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| ES2167391T3 (es) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
| EP1621206A1 (de) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimäre Zytokine und ihre Verwendung |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| JP3342873B2 (ja) | 1995-03-10 | 2002-11-11 | ジェネンテク・インコーポレイテッド | ｇａｓ６による受容体活性化 |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| AU5893796A (en) | 1995-06-07 | 1996-12-30 | Novo Nordisk A/S | Modification of polypeptides |
| AU5985996A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| IL122718A0 (en) | 1995-06-30 | 1998-08-16 | Lilly Co Eli | Methods for treating diabetes |
| US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
| US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| JP3840262B2 (ja) | 1995-10-23 | 2006-11-01 | ザ チルドレンズ メディカル センター コーポレイション | 治療用の抗血管新生組成物および方法 |
| WO1997020062A1 (en) | 1995-12-01 | 1997-06-05 | University Of Massachusetts | Il-12 p40 subunit fusion polypeptides and uses thereof |
| RU2178307C2 (ru) | 1995-12-27 | 2002-01-20 | Джинентех Инк. | Производные ов-протеина |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
| US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| AU2527397A (en) | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| CA2258593A1 (en) | 1996-07-02 | 1998-01-08 | Abraham Nudelman | Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| WO1998006752A1 (en) | 1996-08-16 | 1998-02-19 | The Rockefeller University | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| US6737057B1 (en) | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP2001521520A (ja) | 1997-04-11 | 2001-11-06 | ジー．ディー．サール アンド カンパニー | 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト |
| CN1202862C (zh) | 1997-04-17 | 2005-05-25 | 安姆根有限公司 | 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法 |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| AU8182298A (en) | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| PT1037927E (pt) | 1997-12-08 | 2004-10-29 | Emd Lexigen Res Ct Corp | Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral |
| US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| CN1204147C (zh) | 1998-02-25 | 2005-06-01 | 利思进药品公司 | 提高以抗体为基础的融合蛋白的循环半衰期的方法 |
| ATE329622T1 (de) | 1998-04-15 | 2006-07-15 | Lexigen Pharm Corp | Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor |
| RU2217168C2 (ru) | 1998-04-17 | 2003-11-27 | Лексиген Фармасьютикэлс Корпорейшн | Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина |
| WO1999054484A1 (en) * | 1998-04-20 | 1999-10-28 | The Regents Of The University Of California | Modified immunoglobulin molecules and methods for use thereof |
| EP1088888A4 (de) | 1998-05-14 | 2005-03-16 | Merck Patent Gmbh | Fusionierte proteine |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| JP2002517186A (ja) | 1998-06-03 | 2002-06-18 | ザ チルドレンズ メディカル センター コーポレイション | エンドスタチンタンパク質を含むタンパク質オリゴマー組成物およびその使用方法 |
| DE69933216T2 (de) | 1998-06-15 | 2007-09-20 | GTC Biotherapeutics, Inc., Framingham | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| EP1105427A2 (de) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Herstellung von modifizierten molekülen mit mit erhöhten halbwertszeiten |
| ATE462725T1 (de) | 1998-08-25 | 2010-04-15 | Merck Patent Gmbh | Expression und export von angiostatin und endostatin als immunofusins |
| US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
| US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
| ATE355303T1 (de) | 1998-10-23 | 2006-03-15 | Amgen Inc | Methoden und zusammensetzungen zur prävention und behandlung der anämie |
| EP1051432B1 (de) | 1998-12-08 | 2007-01-24 | Biovation Limited | Verfahren zur verminderung der immunogenität von proteinen |
| BR0007414A (pt) | 1999-01-07 | 2001-10-16 | Lexigen Pharm Corp | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc |
| WO2000067761A1 (en) | 1999-05-06 | 2000-11-16 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
| AU766507B2 (en) | 1999-05-07 | 2003-10-16 | Genentech Inc. | Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| KR20020018197A (ko) | 1999-05-19 | 2002-03-07 | 추후보정 | Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
| AU5617900A (en) | 1999-06-17 | 2001-01-09 | Robert C. Gallo | Chimeric chemokine-antigen polypeptides and uses therefor |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| BR0013231A (pt) | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Complexos citocina-anticorpo múltiplos |
| EP1228214A2 (de) * | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietinformen mit verbesserten eigenschaften |
| US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| PT1257297E (pt) | 2000-02-24 | 2006-12-29 | Philogen Spa | Composições e método para tratamento da angiogénese em lesões patológicas |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU2001263149A1 (en) | 2000-05-12 | 2001-11-26 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
| JP5390055B2 (ja) | 2000-06-29 | 2014-01-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強 |
| MXPA03006294A (es) | 2001-01-18 | 2003-09-16 | Merck Patent Gmbh | Proteinas de fusion disfuncionales con actividad glucocerebrosidasa. |
| PL362324A1 (en) | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| HUP0303428A2 (hu) | 2001-03-07 | 2004-01-28 | Merck Patent Gmbh. | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| KR100900166B1 (ko) | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | 재조합 종양 특이적 항체 및 이들의 용도 |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| ATE542137T1 (de) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| WO2003077834A2 (en) | 2002-03-15 | 2003-09-25 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| CN100432105C (zh) | 2002-12-17 | 2008-11-12 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
| US20050069521A1 (en) | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| EP1673395A1 (de) * | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Veränderungen der serum-halbwertszeiten von fc-fusionsprotein durch mutagenese der position 250, 314 und/oder 428 der schweren kette der konstanten region von ig |
| PT1699822E (pt) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP2270050B1 (de) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-C19 Antikörper mit reduzierter Immunogenizität |
| EP1966238B1 (de) | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40-varianten mit verbesserter stabilität |
| EA200870130A1 (ru) | 2005-12-30 | 2009-02-27 | Мерк Патент Гмбх | Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2008003473A2 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| US7622522B2 (en) | 2007-09-27 | 2009-11-24 | Sabic Innovative Plastics Ip B.V. | Flame-retardant poly(arylene ether) composition and its use as a covering for coated wire |
-
2001
- 2001-02-09 JP JP2001558103A patent/JP5179689B2/ja not_active Expired - Fee Related
- 2001-02-09 US US09/780,668 patent/US7091321B2/en not_active Expired - Lifetime
- 2001-02-09 AT AT01916083T patent/ATE336514T1/de active
- 2001-02-09 MX MXPA02007733A patent/MXPA02007733A/es active IP Right Grant
- 2001-02-09 CN CN018058639A patent/CN1406249B/zh not_active Expired - Lifetime
- 2001-02-09 ES ES01916083T patent/ES2269366T3/es not_active Expired - Lifetime
- 2001-02-09 EP EP01916083A patent/EP1252192B1/de not_active Expired - Lifetime
- 2001-02-09 PT PT01916083T patent/PT1252192E/pt unknown
- 2001-02-09 DE DE60122286T patent/DE60122286T2/de not_active Expired - Lifetime
- 2001-02-09 CA CA2399832A patent/CA2399832C/en not_active Expired - Lifetime
- 2001-02-09 AU AU4314801A patent/AU4314801A/xx active Pending
- 2001-02-09 WO PCT/US2001/004455 patent/WO2001058957A2/en not_active Ceased
- 2001-02-09 HU HU0204475A patent/HUP0204475A2/hu unknown
- 2001-02-09 DK DK01916083T patent/DK1252192T3/da active
-
2002
- 2002-08-09 NO NO20023774A patent/NO20023774D0/no not_active Application Discontinuation
-
2005
- 2005-11-07 US US11/268,191 patent/US7507406B2/en not_active Expired - Lifetime
-
2006
- 2006-10-24 CY CY20061101528T patent/CY1105725T1/el unknown
-
2009
- 2009-01-27 US US12/360,682 patent/US7790415B2/en not_active Expired - Fee Related
-
2012
- 2012-05-10 JP JP2012108394A patent/JP5572665B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1406249A (zh) | 2003-03-26 |
| ATE336514T1 (de) | 2006-09-15 |
| US7790415B2 (en) | 2010-09-07 |
| CN1406249B (zh) | 2010-06-16 |
| DE60122286D1 (de) | 2006-09-28 |
| US20060034836A1 (en) | 2006-02-16 |
| NO20023774L (no) | 2002-08-09 |
| DE60122286T2 (de) | 2007-08-02 |
| DK1252192T3 (da) | 2006-11-20 |
| MXPA02007733A (es) | 2004-09-10 |
| PT1252192E (pt) | 2007-01-31 |
| NO20023774D0 (no) | 2002-08-09 |
| US7507406B2 (en) | 2009-03-24 |
| JP2012176969A (ja) | 2012-09-13 |
| JP2003522200A (ja) | 2003-07-22 |
| EP1252192A2 (de) | 2002-10-30 |
| ES2269366T3 (es) | 2007-04-01 |
| CA2399832C (en) | 2011-09-20 |
| CA2399832A1 (en) | 2001-08-16 |
| EP1252192B1 (de) | 2006-08-16 |
| JP5572665B2 (ja) | 2014-08-13 |
| CY1105725T1 (el) | 2010-12-22 |
| AU4314801A (en) | 2001-08-20 |
| JP5179689B2 (ja) | 2013-04-10 |
| WO2001058957A3 (en) | 2002-05-02 |
| US20020147311A1 (en) | 2002-10-10 |
| US7091321B2 (en) | 2006-08-15 |
| WO2001058957A2 (en) | 2001-08-16 |
| US20090264627A1 (en) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023774L (no) | Ökning av antistoffbaserte fusjonsproteiners halveringstid i blodomlöpet | |
| EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
| DK1427750T3 (da) | Modificerede transferrin-fusionsproteiner | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
| CY1118037T1 (el) | Αντισωματα εναντι του αβητα και h χρηση τους | |
| DE69528064D1 (de) | Neuartige peptide | |
| CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
| CY1111831T1 (el) | Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο | |
| DE69933216D1 (de) | Erythropoietin-analog-menschliches serum-albumin fusionsprotein | |
| BR0112111A (pt) | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina | |
| DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
| DE60144145D1 (de) | Subtilisin-variante | |
| DE69434413D1 (de) | Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| WO2003065003A3 (en) | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof | |
| DE60228603D1 (de) | Antigene und vektoren für impfung | |
| DK1539221T3 (da) | Transferrin-fusionsproteinbiblioteker | |
| WO2004035733A3 (en) | Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof | |
| BRPI0204599B8 (pt) | kit para a detecção simultânea de anticorpo para hcv e antígeno de hcv | |
| DE69932644D1 (de) | Menschliches Protein mit in vitro antiproliferativer Aktivität. | |
| EA199900663A1 (ru) | Новые белки, связывающиеся с рецептором 1 интерферона, кодирующая их днк и способы модуляции клеточного ответа на интерфероны | |
| ECSP993285A (es) | Sintesis recombinante de beta lipotropina y otros peptidos | |
| ATE417105T1 (de) | Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins | |
| AR037939A1 (es) | Receptor novedoso acoplado a la proteina g, gave7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |